drugset / Trial / NCT07069725
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Phase 1
Active not recruiting
7 enrolled
AstraZeneca
CTC Clinical Trial Consultants AB · collabKarolinska Institutet · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
Timeline
- Start
- 2025-05-26
- Primary completion
- 2026-07-06
- Completion
- 2026-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD2389 | Small molecule | — | Oral |